Cuvitru (Human Normal Immunoglobulin Vials) 2 g/10ml

Cuvitru is a human normal immunoglobulin therapy provided in 2 g/10ml vials for subcutaneous administration. This ready-to-use solution supports immune system function in certain conditions. Store below 25°C to maintain stability.

Strength

2 g/10ml

Pack Size

Storage

Below 25°C

Manufacturer / TM Owner

Takeda Pharma AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Human normal immunoglobulin like Cuvitru is used to support immune function in people with primary immunodeficiency. It may also be used for immune modulation in specific autoimmune or inflammatory conditions. Ask your healthcare provider what this therapy is used for in your case.

Side Effects

Cuvitru provides antibodies that help strengthen the immune response. Users may notice improved resistance to common infections after regular use. Some people report reduced fatigue or illness severity with consistent therapy.

Precautions & Warnings

Keep vials in their original packaging until use to protect from light. Do not freeze or shake the product. Always check the solution for particles or discoloration before use. Discard any unused portion as directed by your pharmacist.

Avoid Interactions

Cuvitru may interact with live vaccines, reducing their effectiveness. Avoid receiving live vaccines shortly before or after treatment without consulting your doctor. Other drug interactions are uncommon but inform your healthcare provider about all medications you take.

Frequently Asked Questions

Cuvitru is given as a subcutaneous injection, typically under the skin of the abdomen, thigh, or upper arm. A healthcare professional or trained caregiver usually performs the administration.

Contact your healthcare provider if you miss a scheduled dose. Do not double the dose to catch up unless advised to do so by a medical professional.

Only use Cuvitru during pregnancy if clearly needed and prescribed by your doctor. Discuss potential risks and benefits with your healthcare provider before starting treatment.

Store Cuvitru below 25°C in its original packaging. Do not freeze or expose to direct sunlight. Keep out of reach of children.

Common side effects may include redness, swelling, or itching at the injection site. Some users report headache or fatigue. Report persistent reactions to your healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.